Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1444169
This article is part of the Research Topic Clinical Pharmacist Service Promotes the Improvement of Medical Quality Volume II View all 4 articles

Initial dosage optimization of olanzapine in patients with bipolar disorder based on model-informed precision dosing: a study from the real world

Provisionally accepted
Xiao Chen Xiao Chen 1Hu Ke Hu Ke 1Hao-Zhe Shi Hao-Zhe Shi 1Liang Chen Liang Chen 1Yi-Jia Zhang Yi-Jia Zhang 1Sumei He Sumei He 2*Cun Zhang Cun Zhang 1*Dongdong Wang Dongdong Wang 1*
  • 1 Xuzhou Medical University, Xuzhou, China
  • 2 Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China

The final, formatted version of the article will be published soon.

    Objectives: Olanzapine is used for treating bipolar disorder (BPD), however the optimal initial dosing regimen is unclear. The present study aimed to investigate optimal olanzapine initial dosage in patients with BPD via model-informed precision dosing (MIPD) based on real world study. Methods: 39 patients with BPD from real world study were collected to construct MIPD model. Results: Weight, combined used quetiapine influenced olanzapine clearances in patients with BPD, where the clearance rates were 0.152:1 in patients with or without quetiapine under the same weight, respectively. We simulated once a day or twice a day olanzapine doses, among which twice a day was optimal. Without quetiapine, for twice a day olanzapine doses, 0.80, 0.70, 0.60 mg/kg/day were suitable for 40-56, 56-74, and 74-100 kg BPD patients, respectively. With quetiapine, for twice a day olanzapine dose, 0.05 mg/kg/day were suitable for 40-100 kg BPD patients. Conclusions: It was the first time to investigate optimal olanzapine initial dosage in patients with BPD via MIPD based on real world study, providing clinical reference for precision medication of olanzapine in BPD patients.

    Keywords: initial dosage optimization, olanzapine, Bipolar Disorder, Model-informed precision dosing, Real world study

    Received: 05 Jun 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Chen, Ke, Shi, Chen, Zhang, He, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Sumei He, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China
    Cun Zhang, Xuzhou Medical University, Xuzhou, China
    Dongdong Wang, Xuzhou Medical University, Xuzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.